All Updates

All Updates

icon
Filter
Product updates
Tempus announces clinical launch of minimal residual disease test portfolio
Precision Medicine
May 31, 2024
Last week:
Partnerships
Geographic expansion
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Industry news
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
Precision Medicine

Precision Medicine

May 31, 2024

Tempus announces clinical launch of minimal residual disease test portfolio

Product updates

  • Tempus has launched a clinical trial of its minimal residual disease (MRD) test portfolio, including the xM test and the NeXT Personal® Dx test. These tests aim to identify residual illness or early signs of cancer recurrence and monitor the response to immunotherapy.

  • The portfolio features a tumor-naïve test, xM, that can detect circulating tumor DNA (ctDNA) in patients' blood following curative surgery for early-stage colorectal cancer. The tumor-informed test, NeXT Personal Dx, which is co-commercialized with Personalis, employs whole-genome sequencing to detect minute traces of ctDNA in the blood of patients after curative treatments for early non-small-cell lung cancer and breast cancer and can be used for immunotherapy monitoring in late-stage cancers. This assay can identify up to 1,800 somatic mutations unique to a patient’s tumor and offer both a rapid, tumor-naïve test and an ultra-sensitive, tumor-informed test.

  • According to Tempus, the main advantages of these new tests come from their ability to provide early-stage cancer insights. This early detection can significantly impact a patient's care plan and outcome. Furthermore, offering two types of tests provides physicians with the necessary flexibility to address the individual needs of each of their patients.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.